Acura Pharmaceuticals ACUR Stock Purchasers File Securities Fraud Class Action Lawsuit Complaint Against Acura Pharmaceuticals Over Acurox Tablets.
A securities fraud class action lawsuit has been filed against Acura Pharmaceuticals, Inc. (“Acura Pharmaceuticals” or “ACUR”) and certain Acura Pharmaceuticals officers and/or directors (collectively “Defendants”) in the United States District Court for the Northern District of Illinois on behalf of a class consisting of all purchasers of Acura Pharmaceuticals common stock (symbol: ACUR) during the period between February 21, 2006 and April 22, 2010, inclusive (the “Class Period”), alleging that Acura Pharmaceuticals, a specialty pharmaceutical company engaged in research, development and manufacture of product candidates providing abuse deterrent features and benefits, and certain of Acura Pharmaceuticals’s officers and/or directors, violated federal securities fraud laws by purportedly issuing false and misleading statements regarding Acurox, an orally administered immediate release tablet containing oxycodone as its active ingredient and niacin as an oral abuse-deterrent, according to class action lawsuit news reports.
If You Have Thoughts On The Acura Pharmaceuticals Acurox Securities Fraud Class Action Lawsuit, Share Your Class Action Comments Below.